|
|
SWE |
|
Vaxjo ID |
198 |
|
Vaccine Adjuvant Name |
SWE |
|
Adjuvant VO ID |
VO_0005388
|
|
Description |
squalene oil in water emulstion that induces mixed Th1/Th2 response |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
Switzerland (Vaccine formulation institute) |
|
Host Species for Testing |
2 |
|
Second Host Species for Testing |
3 |
|
Components |
Shark liver squalene purchased from Sigma–Aldrich (St. Louis, MO); egg yolk phosphatidylcholine (PC) and 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) obtained from Avanti Polar Lipids, Inc. (Alabaster, AL); and Pluronic F-68 NF prill surfactant obtained courtesy of BASF (Florham Park, NJ). The buffer components, monobasic and dibasic ammonium phosphate, were obtained from Riedel-de Haën (Seelze, Germany) and Spectrum Chemical (Gardena, CA). Distilled water was deionized with a Barnstead E-pure for use in all formulations. Water for injection (WFI) was obtained from Abbot Laboratories (North Chicago, IL |
|
Storage |
2-8C |
|
Preparation |
Emulsions were prepared by mixing a buffered aqueous phase (ammonium phosphate buffer, detergent, glycerol) with an oil phase (squalene or Miglyol, phosphatidylcholine, optional α-tocopherol), followed by high-shear mixing and high-pressure homogenization (~30,000 psi for 12 passes). The oil phase was sonicated at ~50 °C until dissolved. Phases were combined at a 90:10 ratio and stored at 2–8 °C |
| References |
(Lawrenz, 2024): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=50]
Wong et al., 2022: Wong TY, Russ BP, Lee KS, Miller OA, Kang J, Cooper M, Winters MT, Rodriguez-Aponte SA, Dalvie NC, Johnston RS, Rader NA, Wong ZY, Cyphert HA, Martinez I, Shaligram U, Batwal S, Lothe R, Chandrasekaran R, Nagar G, Rajurkar M, Rao H, Bevere JR, Barbier M, Love JC, Damron FH. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge. mSphere. 2022; 7(4); e0024322. [PubMed: 35968964].
|
|
